Tosk, Inc.

5 articles about Tosk, Inc.

• Tosk’s Successful New Chemotherapy Side-Effect-Prevention Drug Discovered Using Fruit Flies

  10/15/2019

  Tosk, Inc.’s recent success in its Phase 2a, placebo-controlled, clinical study of TK-90 in head and neck cancer patients, validates the effectiveness of the company’s use of fruit flies as a powerful discovery tool in its research, according to Vice President of Research and Development, Bill Garland.

• Tosk Produces New Corporate Video

  6/5/2019

  Tosk, Inc. announced today the release of a new video describing the company’s work and proprietary technology intended to transform the treatment of cancer and other diseases.

• First Drug Discovered in a Fruit Fly Used in Cancer Patients

  4/30/2019

  Tosk, Inc. announced today that its patented drug, TK-90, which prevents the adverse side effects of frontline cancer therapies, succeeded in human clinical studies involving 25 head-and-neck cancer patients.

• National Cancer Institute Awards Tosk $2 Million Cancer Drug Development Grant

  2/15/2018

  Tosk, Inc. announced today that it has received a two-year, $2 million Phase II SIBR grant from the National Cancer Institute (NCI) to support its kRAS oncogene drug research and development program, a high priority for the NCI.

• Tosk Reports Initiation of POC Human Studies

  1/4/2018

  Tosk, Inc. reported today the completion of Phase 1 safety trials and the initiation of POC studies in human cancer patients for the prevention of mucositis side effects using its drug TK-90.